<DOC>
	<DOCNO>NCT00327743</DOCNO>
	<brief_summary>The goal phase I-II clinical research study find high safe dose XRP9881 capecitabine give combination treatment metastatic breast cancer patient previously treat taxanes anthracyclines . The safety effectiveness combination also study . Patients participate study ask give additional blood sample look level study drug blood .</brief_summary>
	<brief_title>Combination Study New Taxane Capecitabine Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Histologically cytologically proven diagnosis breast adenocarcinoma metastatic locally recurrent inoperable curative intent . Prior treatment standard regimen anthracycline taxane . Female patient least 18 year old . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) : 02 Adequate organ bone marrow function Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ( For part I component , patient nonmeasurable disease accept . ) Resolution clinically significant toxic effect Completion prior therapy ≥ 3 week prior registration . Patients bisphosphonate therapy may continue therapy . Patients must either postmenopausal , surgically sterile , use effective contraception . Willing able comply study procedure sign informed consent History second malignancy within last 5 year ( except adequately treat basal cell squamous cell skin cancer , situ carcinoma cervix uterus ) . Patients receive one adjuvant regimen one metastatic regimen Known brain leptomeningeal disease . Concurrent treatment another clinical trial cancer therapy include chemotherapy , biological therapy , hormonal therapy , radiotherapy , chemoembolization therapy , cryotherapy , target noncytotoxic therapy , patient plan receive treatment study . Prior treatment capecitabine , XRP9881 , investigational chemotherapy . History hypersensitivity taxanes , Polysorbate80 , compound similar chemical structure . Patients know intolerance fluoropyrimidines patient know dihydropyrimidine dehydrogenase ( DPD ) deficiency . Concurrent treatment potent inhibitor cytochrome P450 3A4 , patient plan receive treatment . For patient receive treatment agent , oneweek washout period require prior registration . Peripheral neuropathy grade ≥ 2 . Any follow within 6 month prior registration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft surgery , clinically symptomatic uncontrolled cardiovascular disease , clinically significant cardiac arrhythmia ( grade 34 ) . History inflammatory bowel disease chronic diarrhea . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication . Other severe acute chronic medical psychiatric condition , significant laboratory abnormality require investigation may cause undue risk patient 's safety . Known human immunodeficiency virus ( HIV ) infection require treatment acquire immunodeficiencysyndrome ( AIDS ) relate illness . Patients pregnant breastfeeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Cancer Alternative Therapies</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>